IBDEI0H1 ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,7672,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7672,1,3,0)
;;=3^DM Type 2 w/ CKD
;;^UTILITY(U,$J,358.3,7672,1,4,0)
;;=4^E11.22
;;^UTILITY(U,$J,358.3,7672,2)
;;=^5002630
;;^UTILITY(U,$J,358.3,7673,0)
;;=E11.319^^39^386^24
;;^UTILITY(U,$J,358.3,7673,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7673,1,3,0)
;;=3^DM Type 2 w/ Retinopathy Unspec w/o Macular Edema
;;^UTILITY(U,$J,358.3,7673,1,4,0)
;;=4^E11.319
;;^UTILITY(U,$J,358.3,7673,2)
;;=^5002633
;;^UTILITY(U,$J,358.3,7674,0)
;;=G40.909^^39^386^76
;;^UTILITY(U,$J,358.3,7674,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7674,1,3,0)
;;=3^Seizure Disorder NOS
;;^UTILITY(U,$J,358.3,7674,1,4,0)
;;=4^G40.909
;;^UTILITY(U,$J,358.3,7674,2)
;;=^5003865
;;^UTILITY(U,$J,358.3,7675,0)
;;=N52.9^^39^386^30
;;^UTILITY(U,$J,358.3,7675,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7675,1,3,0)
;;=3^Erectile Dysfuntion,Unspec
;;^UTILITY(U,$J,358.3,7675,1,4,0)
;;=4^N52.9
;;^UTILITY(U,$J,358.3,7675,2)
;;=^5015763
;;^UTILITY(U,$J,358.3,7676,0)
;;=I50.22^^39^386^39
;;^UTILITY(U,$J,358.3,7676,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7676,1,3,0)
;;=3^Heart Failure,Systolic,Chronic
;;^UTILITY(U,$J,358.3,7676,1,4,0)
;;=4^I50.22
;;^UTILITY(U,$J,358.3,7676,2)
;;=^5007241
;;^UTILITY(U,$J,358.3,7677,0)
;;=I50.32^^39^386^37
;;^UTILITY(U,$J,358.3,7677,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7677,1,3,0)
;;=3^Heart Failure,Diastolic,Chronic
;;^UTILITY(U,$J,358.3,7677,1,4,0)
;;=4^I50.32
;;^UTILITY(U,$J,358.3,7677,2)
;;=^5007245
;;^UTILITY(U,$J,358.3,7678,0)
;;=I50.42^^39^386^38
;;^UTILITY(U,$J,358.3,7678,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7678,1,3,0)
;;=3^Heart Failure,Systolic & Diastolic,Chronic
;;^UTILITY(U,$J,358.3,7678,1,4,0)
;;=4^I50.42
;;^UTILITY(U,$J,358.3,7678,2)
;;=^5007249
;;^UTILITY(U,$J,358.3,7679,0)
;;=I13.0^^39^386^32
;;^UTILITY(U,$J,358.3,7679,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7679,1,3,0)
;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 1-4 Chr Kdny
;;^UTILITY(U,$J,358.3,7679,1,4,0)
;;=4^I13.0
;;^UTILITY(U,$J,358.3,7679,2)
;;=^5007067
;;^UTILITY(U,$J,358.3,7680,0)
;;=I13.2^^39^386^33
;;^UTILITY(U,$J,358.3,7680,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7680,1,3,0)
;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 5 Chr Kdny
;;^UTILITY(U,$J,358.3,7680,1,4,0)
;;=4^I13.2
;;^UTILITY(U,$J,358.3,7680,2)
;;=^5007070
;;^UTILITY(U,$J,358.3,7681,0)
;;=I13.10^^39^386^34
;;^UTILITY(U,$J,358.3,7681,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7681,1,3,0)
;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 1-4 Chr Kdny
;;^UTILITY(U,$J,358.3,7681,1,4,0)
;;=4^I13.10
;;^UTILITY(U,$J,358.3,7681,2)
;;=^5007068
;;^UTILITY(U,$J,358.3,7682,0)
;;=I13.11^^39^386^35
;;^UTILITY(U,$J,358.3,7682,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7682,1,3,0)
;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 5 Chr Kdny
;;^UTILITY(U,$J,358.3,7682,1,4,0)
;;=4^I13.11
;;^UTILITY(U,$J,358.3,7682,2)
;;=^5007069
;;^UTILITY(U,$J,358.3,7683,0)
;;=E03.9^^39^386^45
;;^UTILITY(U,$J,358.3,7683,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7683,1,3,0)
;;=3^Hypothyroidism,Unspec
;;^UTILITY(U,$J,358.3,7683,1,4,0)
;;=4^E03.9
;;^UTILITY(U,$J,358.3,7683,2)
;;=^5002476
;;^UTILITY(U,$J,358.3,7684,0)
;;=C61.^^39^386^49
;;^UTILITY(U,$J,358.3,7684,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7684,1,3,0)
;;=3^Malig Neopl Prostate
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0H1 3764 printed Sep 23, 2025@19:24:31 Page 2
IBDEI0H1 ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,7672,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,7672,1,3,0)
+4 ;;=3^DM Type 2 w/ CKD
+5 ;;^UTILITY(U,$J,358.3,7672,1,4,0)
+6 ;;=4^E11.22
+7 ;;^UTILITY(U,$J,358.3,7672,2)
+8 ;;=^5002630
+9 ;;^UTILITY(U,$J,358.3,7673,0)
+10 ;;=E11.319^^39^386^24
+11 ;;^UTILITY(U,$J,358.3,7673,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,7673,1,3,0)
+14 ;;=3^DM Type 2 w/ Retinopathy Unspec w/o Macular Edema
+15 ;;^UTILITY(U,$J,358.3,7673,1,4,0)
+16 ;;=4^E11.319
+17 ;;^UTILITY(U,$J,358.3,7673,2)
+18 ;;=^5002633
+19 ;;^UTILITY(U,$J,358.3,7674,0)
+20 ;;=G40.909^^39^386^76
+21 ;;^UTILITY(U,$J,358.3,7674,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,7674,1,3,0)
+24 ;;=3^Seizure Disorder NOS
+25 ;;^UTILITY(U,$J,358.3,7674,1,4,0)
+26 ;;=4^G40.909
+27 ;;^UTILITY(U,$J,358.3,7674,2)
+28 ;;=^5003865
+29 ;;^UTILITY(U,$J,358.3,7675,0)
+30 ;;=N52.9^^39^386^30
+31 ;;^UTILITY(U,$J,358.3,7675,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,7675,1,3,0)
+34 ;;=3^Erectile Dysfuntion,Unspec
+35 ;;^UTILITY(U,$J,358.3,7675,1,4,0)
+36 ;;=4^N52.9
+37 ;;^UTILITY(U,$J,358.3,7675,2)
+38 ;;=^5015763
+39 ;;^UTILITY(U,$J,358.3,7676,0)
+40 ;;=I50.22^^39^386^39
+41 ;;^UTILITY(U,$J,358.3,7676,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,7676,1,3,0)
+44 ;;=3^Heart Failure,Systolic,Chronic
+45 ;;^UTILITY(U,$J,358.3,7676,1,4,0)
+46 ;;=4^I50.22
+47 ;;^UTILITY(U,$J,358.3,7676,2)
+48 ;;=^5007241
+49 ;;^UTILITY(U,$J,358.3,7677,0)
+50 ;;=I50.32^^39^386^37
+51 ;;^UTILITY(U,$J,358.3,7677,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,7677,1,3,0)
+54 ;;=3^Heart Failure,Diastolic,Chronic
+55 ;;^UTILITY(U,$J,358.3,7677,1,4,0)
+56 ;;=4^I50.32
+57 ;;^UTILITY(U,$J,358.3,7677,2)
+58 ;;=^5007245
+59 ;;^UTILITY(U,$J,358.3,7678,0)
+60 ;;=I50.42^^39^386^38
+61 ;;^UTILITY(U,$J,358.3,7678,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,7678,1,3,0)
+64 ;;=3^Heart Failure,Systolic & Diastolic,Chronic
+65 ;;^UTILITY(U,$J,358.3,7678,1,4,0)
+66 ;;=4^I50.42
+67 ;;^UTILITY(U,$J,358.3,7678,2)
+68 ;;=^5007249
+69 ;;^UTILITY(U,$J,358.3,7679,0)
+70 ;;=I13.0^^39^386^32
+71 ;;^UTILITY(U,$J,358.3,7679,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,7679,1,3,0)
+74 ;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 1-4 Chr Kdny
+75 ;;^UTILITY(U,$J,358.3,7679,1,4,0)
+76 ;;=4^I13.0
+77 ;;^UTILITY(U,$J,358.3,7679,2)
+78 ;;=^5007067
+79 ;;^UTILITY(U,$J,358.3,7680,0)
+80 ;;=I13.2^^39^386^33
+81 ;;^UTILITY(U,$J,358.3,7680,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,7680,1,3,0)
+84 ;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 5 Chr Kdny
+85 ;;^UTILITY(U,$J,358.3,7680,1,4,0)
+86 ;;=4^I13.2
+87 ;;^UTILITY(U,$J,358.3,7680,2)
+88 ;;=^5007070
+89 ;;^UTILITY(U,$J,358.3,7681,0)
+90 ;;=I13.10^^39^386^34
+91 ;;^UTILITY(U,$J,358.3,7681,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,7681,1,3,0)
+94 ;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 1-4 Chr Kdny
+95 ;;^UTILITY(U,$J,358.3,7681,1,4,0)
+96 ;;=4^I13.10
+97 ;;^UTILITY(U,$J,358.3,7681,2)
+98 ;;=^5007068
+99 ;;^UTILITY(U,$J,358.3,7682,0)
+100 ;;=I13.11^^39^386^35
+101 ;;^UTILITY(U,$J,358.3,7682,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,7682,1,3,0)
+104 ;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 5 Chr Kdny
+105 ;;^UTILITY(U,$J,358.3,7682,1,4,0)
+106 ;;=4^I13.11
+107 ;;^UTILITY(U,$J,358.3,7682,2)
+108 ;;=^5007069
+109 ;;^UTILITY(U,$J,358.3,7683,0)
+110 ;;=E03.9^^39^386^45
+111 ;;^UTILITY(U,$J,358.3,7683,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,7683,1,3,0)
+114 ;;=3^Hypothyroidism,Unspec
+115 ;;^UTILITY(U,$J,358.3,7683,1,4,0)
+116 ;;=4^E03.9
+117 ;;^UTILITY(U,$J,358.3,7683,2)
+118 ;;=^5002476
+119 ;;^UTILITY(U,$J,358.3,7684,0)
+120 ;;=C61.^^39^386^49
+121 ;;^UTILITY(U,$J,358.3,7684,1,0)
+122 ;;=^358.31IA^4^2
+123 ;;^UTILITY(U,$J,358.3,7684,1,3,0)
+124 ;;=3^Malig Neopl Prostate
